Insulin Resistance and Metformin Use on Volume of Benign Thyroid Nodules

• Status: Completed
• Trial end date: 2019-04-17
• Target enrollment: 0
• Participant gender: All

Summary

It has been shown that insulin might be involved in the pathogenesis of thyroid growth.

Objective To evaluate the impact of IR and metformin use on the volume of benign thyroid nodules (TNs).

Methods A randomized clinical trial to placebo (P) or MTF use. Previous fine needle aspiration confirming the diagnosis is necessary to inclusion. Patients will receive similar tablets of MTF and placebo and instruct to take 3 tablets/day of MTF (500mg/tablet). Thyroid volume, as TN volume, will be assess by ultrasound, both in the beginning, six months and one year after randomization, by the same researcher blinded regarding location group. Blood samples to measure: TSH, FT4, TPO-Ab, lipid profile, glucose and insulin were done after 8h fasting.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Hospital Universitário Clementino Fraga Filho
• Treatments: Insulin; Insulin, Globin Zinc; Metformin

Criteria

Inclusion Criteria:

• patients with benign nodules diagnosed by fine needle aspiration biopsy (FNAB)

Exclusion Criteria:

• Nodules with a predominantly cystic pattern

• Eggshell calcification

• Coalescent thyroid nodules (not suitable for size analysis)

• Pregnancy

• Diabetes

• Acromegaly

• Previous use of MTF, levothyroxine, corticoid or any weight loss medication in the past six months

• Hepatic or cardiac insufficiency

• Creatinine levels > 1.4 mg/dL

• MTF intolerance doses < 1.0 gram/day